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ACKGROUND: Since the irst umbilical cord 
blood (UCB) transplant, performed 25 years ago, 
UCB banks have been established worldwide for 
the collection and cryopreservation of UCB for autologous 
and allogeneic transplants.
CONTENT: Much has been learned in a relatively short time 
on the properties of UCB hematopoietic progenitors and their 
clinical application. More interestingly, non-hematopoietic 
stem cells have been isolated from UCB. These cells can 
be grown and differentiated into various tissues including 
bone, cartilage, liver, pancreas, nerve,  muscle and so on. 
The non-hematopoietic stem cells have an advantage over 
other sources of stem cells, such as embryonic stem cells 
or induced pluripotent stem cells, because their supply is 
unlimited, they can be used in autologous or allogeneic 
situations, they need minimal manipulation and they raise 
no ethical concerns. Future studies will test the potential of 
UCB cells for the treatment of several diseases including, 
among other possibilities, diabetes, arthritis, burns, 
neurological disorder and myocardial infarction.
SUMMARY: In addition to hematopoietic stem cells, UCB 
contain a large number of non-hematopoietic stem cells. 
In the absence of ethical concern, the unlimited supply of 
UCB cells explains the increasing interest of using UCB for 
developing regenerative medicine.
KEYWORDS: UCB, transplantation, UCB bank, HSC, 
MSC, CD34, CD133, VSEL
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ATAR BELAKANG: Sejak transplantasi darah 
tali pusat (DTP) pertama yang dilakukan 25 tahun 
yang lalu, telah banyak didirikan bank DTP di 
seluruh dunia untuk menyimpan DTP, untuk dipakai pada 
transplantasi autologus maupun alogenik.
ISI: Banyak yang telah dipelajari dalam waktu yang 
relatif singkat tentang sifat progenitor hematopoietik 
DTP dan aplikasi klinisnya. Yang lebih menarik, sel 
punca non-hematopoietik telah diisolasi dari DTP. Sel ini 
dapat berkembang dan berdiferensiasi menjadi berbagai 
jaringan seperti  tulang, tulang rawan, hati, pankreas, saraf, 
otot dan sebagainya. Sel punca non-hematopoietik ini 
memiliki kelebihan dibanding sel punca sumber lainnya 
seperti sel punca embrionik atau sel punca pluripoten hasil 
induksi, karena sumbernya tidak terbatas, dapat digunakan 
untuk situasi autologus maupun alogenik, membutuhkan 
manipulasi minimal dan tidak menimbulkan masalah etika. 
Penelitian di masa mendatang akan menguji potensi sel DTP 
untuk terapi berbagai penyakit, diantaranya adalah diabetes, 
artritis, luka bakar, gangguan saraf, dan infark miokard.
RINGKASAN: Selain sel punca hematopoietik, DTP 
mengandung banyak sel punca non-hematopoietik. Dengan 
tidak adanya masalah etika, ketersediaan sel DTP yang tidak 
terbatas ini meningkatkan keinginan dalam penggunaan 
DTP untuk pengembangan kedokteran regeneratif.
KATA KUNCI: DTP, transplantasi, bank DTP, HSC, MSC, 
CD34, CD133, VSEL
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The irst umbilical cord blood (UCB) transplant (UCBT) by 
Gluckman et al. was performed in 1988 in a patient with 
Fanconi's anemia.(1) This patient had a healthy human 
leukocyte antigen (HLA)-identical sibling who was shown 
by prenatal testing to be unaffected by the disorder, to have 
a normal karyotype and to be HLA identical to the patient. 
Her cord blood was collected at birth, cryopreserved and 
used after thawing for transplantation. Since the irst UCBT, 
more than 20,000 UCBTs have been reported worldwide and 
more than 620,000 UCB units have been stored in more than 
100 UCB banks.(2) The main practical advantages of using 
UCB as an alternative source of stem cells are the relative 
ease of procurement, the absence of risks for mothers and 
donors, the reduced likelihood of transmitting infections, 
particularly cytomegalovirus (CMV) and the ability to store 
fully tested and  HLA-typed transplants in the frozen state, 
available for immediate use (3).
 UCB bank (UCBB) established criteria for 
standardization of UCB collection, banking, processing and 
cryopreservation for unrelated donor transplants in patients 
with various hematological malignant and non-malignant 
diseases.(3) Recently, the use of UCB stem cells (UCB-SCs) 
in several regenerative medicine applications has expanded 
its clinical utility.
 UCB-SCs contains a mixture of multipotent stem cells 
capable of giving rise to cells derived from the endodermal, 
mesodermal and ectodermal lineages. It has been shown that 
UCB-SCs have the ability to regenerate numerous tissue 
types, and when transplanted into animals and humans, 
have produced measurable functional improvements.(4,5) 
Generally, tissue-derived stem cells have been described 
for neural (6), retinal (7), pancreas (8), skin (9) and liver 
tissues (10). UCB-SCs appear to be unique in their ability 
to undergo pluripotential differentiation. Thus, UCB-SCs 
appear to be a practical substitute for embryonic stem cells 
and are readily available for use in tissue engineering and 
regenerative medicine. Recently clinical trials have begun 
using UCB-SCs to treat type 1 diabetes mellitus (T1DM), 
cerebral palsy and peripheral vascular disease among others.
(4,5) UCB-SCs has transitioned from the laboratory to the 
clinic and numerous patients are currently being treated 
in clinical trials. Other trials will surely rapidly follow, 
including therapies for eyes, joints, wound and spinal cord. 
The key to these advances lies in the pluripotency of UCB-
SCs and their ability to be used in many instances under the 
practice of medicine, as it appears in many instances that it 
Introduction
is possible to merely infuse the stem cells directly without 
timely and costly in vitro culture and differentiation.(11)
Hematopoietic stem cell (HSC) transplantation (HSCT) can 
be performed using stem cells derived from three sources: 
bone marrow (BM), peripheral blood (PB) and UCB. Only 
about 30% of patients in need of HSCT have a matched-
related donor and, although there are currently around 10 
million adult volunteer donors registered worldwide, still 
about 60% of patients will not ind a suitably HLA-matched 
unrelated adult donor, and thus cannot access this potentially 
curative therapy.(12)
 As UCB products are HLA-typed, tested for lack of 
infectious agents and stored, they are immediately available 
upon request and can be shipped to any transplant center 
in the world with relative ease and without delay.(13,14) 
UCB has become such a popular adult stem cell source for 
many reasons, not least because over 130 million births 
worldwide per annum represents the largest, easily available 
stem cell source. It also allows for storage of units from 
ethnic minorities not easily possible within BM registries.
(15) This potentially allows for an increase in the rate of 
matched unrelated donor allogeneic transplants.(16) It has 
also been found that there is a lower risk of graft versus 
host disease (GvHD) when transplanting UCB compared 
to BM.(17) This could be due to the fact that the cells 
transplanted from UCB are more naive and have lower 
HLA protein expression.(16) UCB has been shown to 
contain a higher frequency of early progenitor cells than 
PB or BM.(18) Further indings show that term and pre-
term UCB contain signiicantly higher number of early and 
committed progenitor cells, and that they are better able to 
form colony-forming-unit granulocyte-macrophage (CFU-
GM) when compared to adult PB.(19)
 UCB also contains non-haematopoietic stem or 
progenitor cells including mesenchymal and endothelial 
precursor.(20) Even more recently UCB is becoming a real 
player in the regenerative medicine ield. There are many 
groups looking to develop tissues for either transplantation 
or drug testing with many successes.(21) It has become a 
real alternative to BM and PB as a source of adult stem 
cells to treat multiple diseases. More than 85 conditions 
can currently be treated using this stem cell source, such as 
the previously mentioned Fanconi’s anemia, a BM failure 
disorder (1), metabolic disorders like Krabbe’s disease 
(22) and immune defects like severe combined immune 
deiciency (SCID) (23). Well over 1 million UCB have been 
UCB-SCs
 ͳͳ͹
UCB-SCs in Regenerative Medicine (Meiliana A, et al.)
Indones  Biomed J.  2014; 6(3): 115-22DOI: 10.18585/inabj.v6i3.25
stored globally in the last 10 years. Already, over 20,000 
transplants been performed using UCB for haematopoietic 
reconstitution alone, now this potential is joined in the 
regenerative medicine.(21)
UCBB has gained signiicant interest in recent years because 
of the success of UCBT and its more recent applications 
within regenerative medicine. Both public and private 
banking facilities have been established over the past 20 
years to facilitate these endeavors.
 Generally, UCB samples are red cell- and volume-
reduced prior to cryopreservation, in order to facilitate 
banking and minimize costs. Samples may be frozen using 
a variety of media, and can be stored in either cryovials or 
cryobags, generally in a limited number of frozen aliquots. 
The storage containers may also be overwrapped with a 
plastic protective sheath for protection from contact with 
the liquid nitrogen (LN
2
) itself, as well as a barrier to sample 
contamination.(24) Two of the most critical steps in the 
banking process are the cryopreservation and long-term LN
2
 
storage of the sample in such a fashion that the sample will 
be viable and usable decades into the future.(24)
 Finally, great concern was raised in the mid-1990s 
over potential cross-sample contamination during liquid-
phase LN
2
 storage, after the demonstration that pathogenic 
viruses and other microbial pathogens could survive long-
term direct contact with LN
2
 and could infect other samples 
stored in the same dewar.(25,26)
 While donor-speciic factors probably impact on the 
potency of a UCB unit (27), the collection, processing, 
distribution and infusion stages may also affect the potency 
of this stem cell product, whatever processing technology a 
laboratory chooses, the goal is to achieve maximal recovery 
of total nucleated cells (TNC), mononuclear cells (MNCs), 
CD34+ cells, CFU, progenitor cells and stem cells.(28) 
While the overall cellular recovery declines as a result of the 
freezing process, the overall potency may be preserved for 
more than 15 years if the UCB is maintained below -150°C.
(29)
 Currently the United States Food and Drug 
Administration (US FDA) recommends evaluation of 
potency through assessment of the following in vitro 
assays: TNC count, cell viability and CD34 analysis. TNC 
are measured using automated hematology analyzers, the 
CD34 assay is performed using low cytometry, and the 
CFU assay is accomplished using a methylcellulose-based 
media impregnated with cytokines.(28) There is increasing 
evidence that UCB unit potency should be assessed post-
cryopreservation because events associated with freezing 
and storage can affect subsequent cellular viability and 
overall UCB potency.(28)
 Although there are many beneits to using UCB for 
transplantation there is one major limitation: the TNC 
count and cell number recoverable from a single unit. This 
is affected by unit size, maternal factors such as number 
of previous pregnancies and age of mother (30), limited 
volumes available from each sample, but not least the 
processing method used. Together, these factors highlight 
the need to make processing as eficient as possible (31) 
to make UCBB a real option. Many methods are currently 
available. Techniques were varied; from density gradient 
separation, like Lymphoprep or Ficoll-Paque (32), rouleaux 
formation using Hetastarch (HES), a starch based method 
causing red cells to clump (33), plasma depletion; a simple 
volume reduction method which avoids the addition of any 
chemicals and simply removes the plasma (34), a novel 
closed separation kit, known as PrepaCyte-CB which offers 
rapid and speciic cell separation (35), and the only fully 
automated system, provided by Biosafe, known as the 
‘Sepax’ machine (36). PrepaCyte-CB and an automated 
centrifugal machine, Sepax gives the highest recovery of 
nucleated cells, an average of 78.8% (SD±21.36).(21)
 Fifteen to 24% of patients receiving UCBT do not 
engraft. One potential cause of engraftment failure is a loss 
of reconstituting HSC potency that may have occurred at 
some stage during UCB collection, processing, storage, 
shipment and infusion.(28) The National Marrow Donor 
Program (NMDP) Cord Blood Advisory Group can assist 
in the development of assays by providing resources in 
terms of UCB, expertise and access to a network for testing 
assays, once developed, in the ield.(28)
HSC transplantation is a curative approach for a variety of 
malignant and non-malignant diseases.(37-40) Mobilized 
PB, BM and UCB are the main sources of HSC. UCB from 
related and unrelated donors has emerged as a promising 
source of stem cells for a variety of hematological disorders 
and as a supportive therapy for malignant diseases.(41-44) In 
addition to its widespread availability, UCB contains HSCs 
and hematopoietic progenitor cells (HPCs) with higher 
immunological tolerance and higher proliferation ability 
than adult-derived BM (44), however, the low yield of HSCs 
and HPCs in UCB grafts limits their applications in clinics.
(45) For optimum engraftment, current transplantation 
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requires at least 2,500,000 CD34+ cells per kilogram of 
patient body weight.(46) An optimally collected UCB 
donation generates approximately 10,000,000 CD34+ cells, 
which is just adequate for pediatric patients right now.(47)
 UCB HSCs have numerous phenotypic and functional 
characteristics that distinguish them from their adult 
counterparts.(48-52) UCB CD34+ cells are thought to be 
more primitive due to their extensive proliferative capacity, 
their increased ability to generate hematopoietic colonies in 
vitro, their capacity to produce erythroid cells, which contain 
fetal hemoglobins, and the ability of smaller numbers of such 
cells to reconstitute a myeloablated allogeneic recipient.
(48,53)
 While UCB represents a readily available source of 
HSC for transplantation, the low cell dose available in a UCB 
graft correlates with a signiicant delay in hematopoietic 
recovery and a higher risk of primary graft failure.(54,55) 
In order to provide higher absolute numbers of HSC for 
infusion, signiicant efforts have focused on developing 
clinically relevant ex vivo expansion methodologies, many 
of which require an initial enrichment of the progenitor 
population.(56-60)
 For over a decade, CD34 was the gold standard 
identiication selection marker for early HSPC. Recently, 
cells expressing CD133 antigen were considered to be a 
potent substitute for CD34+ cells. Phenotypic and functional 
studies revealed UCB CD133+ populations contain 
higher levels of early HSPC than UCB CD34+ harvested 
populations.(61,62) CD133 was initially considered a 
surface molecule expressed by more primitive HSC and 
endothelial precursor cells expressing vascular endothelial 
growth factor receptor (VEGF-R).(63) Advances in various 
ields have implicated CD133+ cells, which, apart from 
hematopoietic diseases, have also been involved as therapy 
for neurologic and myocardial diseases as well as in other 
research applications.(64) A subpopulation of CD34+ 
CD133+ cells has been described in UCB and identiied as 
more primitive than CD34+ cells (65).
 A number of devices and reagents are commercially 
available for enrichment of CD34+ or CD133+ populations; 
however, these devices must comply with current good 
manufacturing practices (cGMP) if they are to be used 
in the manufacturing process of cellular therapies.(66) 
The CliniMACS Cell Separation System from Miltenyi 
Biotec is currently the only cGMP-grade cell separation 
system available for immunomagnetic separation of CD34+ 
progenitor cells from blood products.(67) CD34+ enrichment 
from UCB units is used increasingly in clinical applications 
involving ex vivo expansion.(67)
UCB-SCs are capable of giving rise to hematopoietic, 
epithelial, endothelial and neural tissues both in vitro and in 
vivo. Thus, UCB-SCs are amenable to treat a wide variety of 
diseases including cardiovascular, ophthalmic, orthopaedic, 
neurological and endocrine diseases.(11) Autologous UCB-
SCs transfusion in children with T1DM is safe but has yet 
to demonstrate eficacy in preserving C-peptide. Larger 
randomized studies as well as 2 years post-infusion follow-
up of this cohort are needed to determine whether autologous 
UCB-based approaches can be used to slow the decline of 
endogenous insulin production in children with T1DM.(68)
 Peripheral arterial disease (PAD) is the most important 
manifestation of systemic atherosclerosis interesting 
lower extremities. The end stage of PAD is critical limb 
ischemia (CLI), whose peculiar symptom is rest pain 
refractory to analgesics lasting more than 2 weeks with or 
without ischemic lesions. The use of autologous stem and 
progenitor cells in cell therapy is limited by their rarity in 
adult PB. In addition, progenitor cells in PAD patients may 
be functionally altered (69). Conversely, UCB contains 
a higher number of progenitor cells, more functional and 
eficient than those in PB, able to induce the formation of 
stable vascular structures inside the ischemic tissues.(70)
 Several innovative therapies with human UCB-
SCs (hUCB-SCs) are currently developing to treat central 
nervous system (CNS) diseases. It has been shown that 
UCB contains multipotent lineage-negative (LinNEG) SCs 
capable of neuronal differentiation. Clinically useful UCB 
samples are stored in different biobanks worldwide, but 
the content and neurogenic properties of LinNEG cells are 
unknown. Jurga et al. showed that Sepax-processed blood 
units contained 10-fold higher number of LinNEG cells 
after cryopreservation in comparison to all other methods.
(71)
 Neonatal hypoxic ischemic (HI) encephalopathy 
due to perinatal asphyxia is an important cause of death 
in the neonatal period, in both developing and developed 
countries.(72) Among the surviving infants, up to 25% will 
have a permanent neurologic deicit in the form of cerebral 
palsy, epilepsy, learning disability, or mental retardation.
(73) Treatment is currently limited to supportive intensive 
care. Given the severity of the problem, it is necessary 
to ind new approaches that could reduce the neurologic 
sequelae of HI newborns (74).
 In the last few years, preclinical studies have shown 
that UCB-SCs injected systemically in the acute phase of 
animal models of stroke, have a therapeutic effect. These 
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cells can reduce the area of brain infarction (75) and the 
inlammation, and increase the regenerative capacity of the 
brain, improving behavioral recovery (76). The potential of 
UCB-SCs to reduce the neurologic deicits associated with 
neonatal hypoxia-ischemia was shown in rats in a study 
that assessed the functional beneits of these cells, using a 
walking-pattern analysis test. The UCB-SCs, when injected 
intraperitoneally 24 hours after the insult, migrated to areas 
of brain damage in large numbers, and alleviated the spastic 
paresis of the animals.(77) Thus, UCB-SCs transplantation 
might rescue striatal neurons from cell death after a neonatal 
HI injury resulting in better functional recovery.(74)
 Cerebral palsy (CP) is the most frequent neurological 
disorder associated with perinatal injury of the developing 
brain. Major brain lesions associated with CP are white 
matter damage (WMD) in preterm infants and cortico- 
subcortical lesions in term newborns. Cell therapy is 
considered promising for the repair of brain damage. The 
hUCB-MNCs are a rich source of various stem cells that 
could be of interest in repairing perinatal brain damage (78).
 Spinal cord injury (SCI) is often characterized by 
immediate and irreversible loss of sensory and motor 
function below the level of injury. Cell transplantation is a 
potential method for certain neurological diseases as well 
as a viable treatment for acute SCI.(79-83) The present 
results indicated CD34+ UCB-SCs accelerated function 
recovery after SCI by governing blood vessel formation 
and restoration. Also, early administration of CD34+ UCB-
SCs was able to increase tissue vitality and the blood vessel 
density, as well as improve behavioral deicits after SCI 
obviously.(84)
 Traumatic brain injury (TBI) is a major public 
health problem associated with death and permanent 
disability worldwide.(85) Both acute and chronic 
symptoms accompany TBI, with survivors suffering from 
progressive post-TBI pathological manifestations such as 
neuroinlammation coupled with behavioral dysfunctions 
including sensory motor deicits, learning and memory 
impairments and a range of neuropsychiatric symptoms 
including anxiety, depression and aggression.(86,87) 
At present, there is signiicant unmet need for clinically 
eficacious therapies for TBI.(88)
 A number of groups have focused on the potential 
of UCB-SCs as a graft source for various intractable 
neurological disorders (e.g., stroke, Parkinson’s disease and 
Huntington’s disease, among others).(89) Moreover, clinical 
trials have been performed to determine the eficacy of 
UCB-SCs in cerebral palsy, inborn metabolic disorders and 
stroke. (90) Combined therapy of UCB-SCs plus granulocyte 
colony stimulating factor (GCSF) synergistically dampened 
traumatic brain injury-induced neuroinlammation while 
signiicantly enhancing endogenous neurogenesis and 
reducing hippocampal cell loss.(91)
 UCB-SCs holds great potential as a source for cellular 
therapy. Mesenchymal stromal cells (MSC) and unrestricted 
somatic stem cells (USSC) found in UCB have been 
reported to differentiate in vivo into osteoblasts, adipocytes 
and neural progenitor cells (92). UCB-SCs cells have been 
used in high doses to delay symptom progression in a 
mouse model of amyotrophic lateral sclerosis (ALS) (93) 
and have been identiied within the central nervous system 
of a patient with Krabbe’s disease 10 months post-UCB-
SC transplant (94), suggesting the persistence of these cells 
as a possible contributor to cellular repair in patients with 
neurodegenerative diseases (95). UCB-MSC could restore 
behavioral functions and attenuate the histopathological 
deicits of experimental autoimmune encephalomyelitis 
mice over the long term (i.e., 50 days) by suppression of 
perivascular immune cell iniltrations and reduction in both 
demyelination and axonal injury in the spinal cord. These 
indings suggest that transplantation of UCB-MSCs may be 
a potential therapy.(96)
SC Researchers at the Steenblock Research Institute in 
San Clemente, California, have been following the cases 
of patients treated with UCB-SCs, as well as tabulating 
results from pilot studies performed abroad involving 
stem  cell therapy for speciic conditions such as cerebral 
palsy in children and MS in adults. The following are but 
a few of the many responses documented as of the date of 
publications.(97)
 A 65 years old man with progressive multiple sclerosis 
(MS) was treated with UCB-SCs in July 2003. Prior to this 
treatment, he could not swallow water normally. Within a 
week of receiving UCB-SCs, he was able to do so without 
a problem. He subsequently made noticeable gains in his 
ability to get around and could communicate more clearly.
(97)
 Ramirez hUCB-SCs therapy program in Mexico has 
treated more than forty children with cerebral palsy since 
March 2003. Eighty ive percent of these children have 
experienced signiicant improvements in motor skills 
and cognitive functions. In one case, a four years old boy 
was cortically blind (a lack of visual functioning despite 
structurally intact eyes), could not speak well, and could 
not get around well prior to therapy with UCB-SCs. Within 
seven months of therapy, however, he was able to track 
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objects with his eyes, was beginning to speak, and could 
move around more ably.(97)
 Jordan Logan, a four years old girl, with a terminal 
genetically based neurological disease called metachromatic 
leukodystrophy (MLD) was treated with 1.5 million UCB-
SCs. MLD is caused partly by a genetic defect in which 
a gene critical to the production of an enzyme called 
arylsulfatase A (ARS-A) is missing or not functioning 
properly. This enzyme makes it possible for a person’s 
body to deal with toxic molecule that we all generate called 
sulfatides children and adults who do not produce ARS-A or 
very little experience declines in their neurological function 
that culminate in disability and death. Within two months 
of her UCB-SCs injection, however, she could track objects 
with her eyes and lift her arms and legs high in the air. 
Eventually, two of the three medications she was on were 
discontinued. Jordan’s story has appeared in numerous 
regional and national newspapers, and also has been the 
focus of TV coverage in Missisippi.(97)
Conclusion
In the last few years, pure UCB-SCs have been utilized 
by physicians to treat a multitude of intractable diseases 
such as progressive MS, ALS, macular degeneration, 
retinitis pigmentosa, stroke, diabetes, and various forms 
of heart disease. This body of patient responses indicates 
that UCB-SCs therapy does produce clinically signiicant 
improvements in many instances. While certainly no cure for 
all, UCB-SC therapy appears to be amassing a respectable 
track record in terms of both safety and clinical utility.
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